Search Results

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.

• Authors : Mathieu, Chantal (AUTHOR); Ásbjörnsdóttir, Björg (AUTHOR); Bajaj, Harpreet S (AUTHOR)

Subjects: TYPE 2 diabetes; INSULIN aspart; INSULIN

• Source: Lancet. Jun2023, Vol. 401 Issue 10392, p1929-1940. 12p.

Record details

Insulin glargine.

• Authors : Bolli, Geremia B; Owens, David R

Subjects: INSULIN therapy; TREATMENT of diabetes; UNITED States. Food & Drug AdministrationEUROPE

• Source: Lancet. 8/5/2000, Vol. 356 Issue 9228, p443. 3p. 1 Color Photograph.

Record details

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

• Authors : Del Prato, Stefano (AUTHOR); Kahn, Steven E (AUTHOR); Pavo, Imre (AUTHOR)

Subjects: TYPE 2 diabetes; ELI Lilly & Co.; CARDIOVASCULAR diseases risk factors

• Source: Lancet. Nov2021, Vol. 398 Issue 10313, p1811-1824. 14p.

Record details

Use of Insulin Glargine in the Management of Neonatal Hyperglycemia in an ELBW Infant.

• Authors : Min J. Hwang; Newman, Robert; Philla, Katherine

Subjects: INSULIN pharmacokinetics; HYPERGLYCEMIA; SUBCUTANEOUS injections

• Source: Pediatrics. 2018 Supplement, Vol. 141, pS399-S403. 5p.

Record details

Surpassing insulin glargine in type 2 diabetes with tirzepatide.

• Authors : Khoo, Bernard (AUTHOR); Tan, Tricia M-M (AUTHOR)

Subjects: TYPE 2 diabetes; INSULIN

• Source: Lancet. Nov2021, Vol. 398 Issue 10313, p1779-1781. 3p.

Record details

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

• Authors : Blonde, Lawrence; Jendle, Johan; Gross, Jorge

Subjects: TYPE 2 diabetes; PEOPLE with diabetes; INSULIN

• Source: Lancet. 5/23/2015, Vol. 385 Issue 9982, p2057-2066. 10p.

Record details

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

• Authors : Bretzel RG (AUTHOR); Nuber U (AUTHOR); Landgraf W (AUTHOR)

• Source: Lancet. 3/29/2008, Vol. 371 Issue 9618, p1073-1084. 12p.

Record details

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

• Authors : Bretzel, Reinhard G; Nuber, Ulrike; Landgraf, Wolfgang

Subjects: INSULIN therapy testing; RANDOMIZED controlled trials; TREATMENT of diabetes

• Source: Lancet. 3/29/2008, Vol. 371 Issue 9618, p1073-1084. 12p. 1 Diagram, 4 Charts, 3 Graphs.

Record details

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

• Authors : Heller, Simon; Buse, John; Fisher, Miles

Subjects: INSULIN research; TREATMENT of diabetes; TYPE 1 diabetes

• Source: Lancet. 4/21/2012, Vol. 379 Issue 9825, p1489-1497. 8p.

Record details

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

• Authors : Zinman, Bernard (AUTHOR); Fulcher, Greg (AUTHOR); Rao, Paturi V. (AUTHOR)

Subjects: INSULIN therapy testing; INJECTIONS; TYPE 2 diabetes treatment

• Source: Lancet. 3/12/2011, Vol. 377 Issue 9769, p924-931. 8p.

Record details